Antibacterial Drugs Market by Drug Classes (Aminoglycosides; Β-Lactams Including Penicillins, Carbapenems, Cephalosporin, Macrolides, Phenicols, Quinolones / Fluoroquinolone, Sulfonamides and Tetracyclines) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs and Forecast 2017-2021

Antibacterial Drugs Market by Drug Classes (Aminoglycosides; Β-Lactams Including Penicillins, Carbapenems, Cephalosporin, Macrolides, Phenicols, Quinolones / Fluoroquinolone, Sulfonamides and Tetracyclines) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs and Forecast 2017-2021

Antibacterial drugs are derived from bacteria or molds or are synthesized de novo and can be classified in several ways – bacteriostatic or bacteriocidal, by chemical structure, according to their mode of action, or according to their spectrum of activity. Antibiotics have many mechanisms of action, including inhibiting cell wall synthesis, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes (e.g. folic acid synthesis). The antibacterial agents possess bactericidal activity which target various parts of bacterial physiology, such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections.

The antibacterial drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug classes (aminoglycosides; β-lactams including penicillins, carbapenems, cephalosporin; macrolides; phenicols; quinolones/fluoroquinolone; sulfonamides; and tetracyclines) and clinical pipeline analysis of phase 1,2 and 3 drugs, and forecasts growth trends (CAGR% – 2017 to 2021).

The global antibacterial drugs market segmentation is based on geography (regional and country based). The global antibacterial drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products,
technologies and services offered, and recent developments. The global antibacterial drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Some of the major players profiled in this report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Allergan plc, GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Merck & Co., Inc., and others.

 

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Antibacterial Drugs Market

1. Drug Class
1.1. Aminoglycosides
1.2. β-Lactams
1.2.1. Penicillins
1.2.2. Carbapenems
1.2.3. Cephalosporins
1.3. Macrolides
1.4. Phenicols
1.5. Quinolones/Fluoroquinolones
1.6. Sulfonamides
1.7. Tetracyclines
1.8. Other Anti-bacterials

2. Pipeline Analysis
2.1. Actoxumab/bezlotoxumab (MK-3415A)
2.2. Arikace
2.3. Cadazolid
2.4. Carbavance (meropenem/RPX7009)
2.5. Ciprofloxacin/Fluocinolone
2.6. Delafloxacin
2.7. Delamanid
2.8. Eravacycline
2.9. Omadacycline (PTK-0796)
2.10. Ozenoxacin
2.11. Plazomycin
2.12. RHB-105
2.13. Solithromycin
2.14. SPL7013
2.15. Surotomycin (MK-4261)
2.16. SYM-1219
2.17. Zempia (E-101)

3. Company Profiles
3.1. Allergan plc.
3.2. AstraZeneca plc.
3.3. Bayer
3.4. Bristol-Myers Squibb Company
3.5. Eli Lilly and
3.6. GlaxoSmithKline plc.
3.7. Johnson & Johnson
3.8. Merck & Co., Inc.
3.9. Novartis AG
3.10. Pfizer, Inc.
3.11. Sanofi

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*